The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme (Q35545489)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

review article

1 reference

title

The telmisartan programme of research tO show Telmisartan End-organ proteCTION (PROTECTION) programme (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) Programme (English)

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Cardiology and cardiovascular medicine

15 March 2024

main subject

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

15 March 2024

Michael Weber

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

language of work or name

1 reference

1 July 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

19 December 2019

https://journals.lww.com/00004872-200307006-00007

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension

15 March 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

page(s)

S37-46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

Blood pressure lowering and renin-angiotensin system blockade

19 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Blood pressure-independent effects in rats with human renin and angiotensinogen genes.

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Left ventricular hypertrophy and angiotensin II antagonists

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Initiation and progression of diabetic nephropathy

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Insulin action is associated with endothelial function in hypertension and type 2 diabetes

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

The role of the renin-angiotensin system in the development of cardiovascular disease

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

The discovery of nitric oxide as the endogenous nitrovasodilator

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Potency of vascular risk factors as the basis for antihypertensive therapy

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Prognostic Significance of Serial Changes in Left Ventricular Mass in Essential Hypertension

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin II AT1 Receptor Antagonism on Cardiac Parameters in Left Ventricular Hypertrophy

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

American Journal of Physiology

15 March 2024

259

H610

Baker

1990

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient.

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Impact of high-normal blood pressure on the risk of cardiovascular disease

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Relevance of blood pressure variation in the circadian onset of cardiovascular events.

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Clinical value of ambulatory blood pressure monitoring

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Hypokalaemia and diuretics: an analysis of publications

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Low dose hydrochlorothiazide (12.5 to 25 mg daily) as monotherapy in black patients with mild to moderate hypertension. Assessment by ambulatory blood pressure monitoring

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

The obesity epidemic: pathophysiology and consequences of obesity

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

American Diabetes Association: clinical practice recommendations 2002

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Perspectives on systolic hypertension. The Framingham study.

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.

15 March 2024

1 reference

https://api.crossref.org/works/10.1097/00004872-200307006-00007

15 March 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json

19 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14513950%20AND%20SRC:MED&resulttype=core&format=json